Home MarketAdinath Bio-Labs Ltd.

Adinath Bio-Labs Ltd. Stock Info: As on 2017-03-07 00:00:00

NO DATA AVAILABLE

Bse

0.30

-0.01(-3.23%)
Change %
52 Week Range
0.19
8.00
0.35
2.00
Open0.30
Day's Range0.29 - 0.33
Value Traded (in ₹ Cr.) 0.00

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 56,838,005.00 25.75%
Mutual Funds/UTI 0.00 0.00%
FII 0.00 0.00%
Employee 0.00 0.00%
Public 100,597,848.00 45.57%
Government 0.00 0.00%
Others 63,306,707.00 28.68%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 5.21
Basic EPS (Rs.) 0.01
Cash EPS 0.01
BVPerShare Excl 1.33
Operating Revenue 0.03
PBDITPerShare 0.02
Dividend 0.00
NPPerShare 0.01
Current Ratio 3.96
Quick Ratio 3.96
PriceToBV 0.14
Earnings 0.03
PBDIT Margin 57.66
PBT Margin 37.70
NP Margin 17.84
Return On Assets 0.48
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 1.00
Total Expenses 0.69
EBITDA 0.46
PBT 0.30
PAT 0.14
Net Income 0.14
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 0.37
Total Expenses 0.34
EBITDA -0.06
PBT 0.02
PAT 0.02
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 22.07
Net worth 29.30
Investments 0.56
Total Liability 29.49
Total debt 0.00
Net block 2.42
Total Assets 29.49
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 22.07
Net worth 29.44
Investments 0.56
Total Liability 29.59
Total debt 0.00
Net block 2.50
Total Assets 29.59
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

537.75 536.2 0.29
520.6544.45

Abbott India Ltd.

4145.05 4172.75 -0.66
40014206.05

Ajanta Pharma Ltd.

1201 1197.6 0.28
11821251.2

Albert David Ltd.

293.95 291 1.01
282.5307.35

Alembic Ltd.

38.65 38.75 -0.26
38.1540

Alembic Pharmaceuticals Ltd.

481.6 482.95 -0.28
469.85515.85

Alkem Laboratories Ltd.

1769.1 1777.35 -0.46
17341819
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

114 115.1 -0.96
109.5127

Aarti Drugs Ltd.

534.5 537 -0.47
524540

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4160 4171.4 -0.27
40354202.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Advik Laboratories Ltd.

4.72 4.52 4.42
4.24.86
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities -2.60
Cash from investing activities 2.58
Cash from financing activities 0.00
Net change in cash -0.02

Stock Held By Mutual Fund Schemes

Infosys Finacle partners with Niki.ai

Infosys Finacle part of EdgeVerve Systems, a wholly-owned subsidiary of Infosys has partnered with Niki.ai, a FinTech start-up to offer chat based commerce to banking customers. With this partnership, Finacle solution suite will be available with Niki.ai's chat-based virtual assistant-Niki. This offering will enable banks to offer its customers a virtual banking assistant for shopping products and services. The joint solution from Finacle and Niki.ai will provide a smart-purchasing chatbot by leveraging natural language processing and machine learning to converse with customers and perform online transactions. The bot will comprehend natural speech text in the context of the customer and will deliver personalized suggestions. The solution will provide banks an opportunity to initiate two-way automated intelligent conversations with customers. Meanwhile, shares of the company closed trading at Rs 911.30 apiece, up 0.31 per cent from the previous close on BSE.

19-09-2017 16:56

Shriram Transport Finance raises Rs 50 cr via bonds

Shriram Transport Finance Company Ltd said it has raised Rs 50 crore by issuing Secured Redeemable Rated Listed Non-Convertible Debenture on private placement basis. “The Allotment Committee - NCDs of the Company in its meeting held today, approved and allotted 500 Secured Redeemable Rated Listed Non-Convertible Debenture of face value of Rs.10,00,000/- (Rupees Ten Lakh only) each, aggregating to Rs. 50 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds with a tenor of 3 years, 11 months and 29 days, carries a coupon rate of 7.60 per cent per annum. Meanwhile, shares of the company closed trading at Rs 1072.65 apiece, down 1.27 per cent from the previous close on BSE.

19-09-2017 16:14

Tata Chemicals sells shares of Tata Global Beverages

Tata Group entity, Tata Chemicals said that it has sold entire shareholding of 4,31,75,140 equity shares of Tata Global Beverages to Tata Sons through a block deal. “The Company has today, i.e., September 19, 2017, sold 4,31,75,140 Equity Shares of face value of Rs. 1/- each of Tata Global Beverages Limited to Tata Sons Limited at price of Rs. 213.35 per share,” it said in a filing to the Bombay Stock Exchange. The chemical company sold these shares at a price of Rs 213.35 per share (excluding brokerage and STT). Promoter group's shareholding stood at 35.76 per cent stake in Tata Global as of June 2017, including Tata Sons' stake of 23.5 per cent that increased to over 30 per cent post block deal. Meanwhile, shares of Tata Chemicals closed trading at Rs 656.95 apiece, up 2.24 per cent from the previous close on BSE.

19-09-2017 15:55

KPTL raises Rs 100 cr on private placement basis

Kalpataru Power Transmission Ltd said that it has raised Rs 100 crore by issuing Non-Convertible Debentures on private placement basis. “The executive committee of board of directors of the company at its meeting held today has approved issuance of listed, rated, unsecured redeemable taxable non convertible debentures of Rs 100 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds carrying a coupon rate of 8.11 per cent p.a. are proposed to be listed on wholesale debt market segment of BSE Ltd. The debentures having a tenure of 5 years from the deemed date of allotment will mature on 27th September 2022, the filing added. Meanwhile, shares of the company closed trading at Rs 362.50 apiece, up 2.13 per cent from the previous close on BSE.

19-09-2017 15:46

Cadila Healthcare enters into agreement with Pharm Aid

Cadila Healthcare Limited, an innovation-driven global healthcare company has said that it has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid Ltd., headquartered in Russia. The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia. Pharm Aid Ltd, has been set up by Nacimbio together with Ishvan Pharmaceuticals Ltd., for the localization of innovative vaccine production in Russia. Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. With an absence of assured supply of indigenously manufactured varicella vaccine, this vaccine does not feature currently in the National Immunisation Programme. The agreement aims to bring in a continuous supply of vaccines which could be included in the critical childhood immunization programme. The demand is estimated at 3 million doses per annum in the Russian Federation alone. Meanwhile, shares of the company were trading at Rs 485.50 apiece, down 0.22 per cent from the previous close at 15:11 hours on BSE.

19-09-2017 15:05

Adinath Bio-Labs Ltd - Standalone Financial Results, Limited Review Report for December 31, 2016

Adinath Bio-Labs Ltd has informed BSE about :

1. Standalone Financial Results for the period ended December 31, 2016

2. Standalone Limited Review for the period ended December 31, 2016

10-Feb-2017 12:47 PM

Adinath Bio-Labs Ltd - Board Meeting Intimation for Results & Closure of Trading Window

Adinath Bio-Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 10, 2017, inter alia, to consider the following business as under:-

- To consider and approve Unaudited financial results for the 3rd quarter ended 31st December, 2016.

Further, the Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 read with Code of Conduct farmed by the Company shall be closed for all designated persons of the Company and their relatives from February 01, 2017 to February 12, 2017 (both days inclusive).

30-Jan-2017 07:03 PM

Adinath Bio-Labs Ltd - Shareholding for the Period Ended December 31, 2016

Adinath Bio-Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016.

18-Jan-2017 06:04 PM

Adinath Bio-Labs Ltd - Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended De

Adinath Bio-Labs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

13-Jan-2017 10:48 AM

Adinath Bio-Labs Ltd - Outcome of Board Meeting

Adinath Bio-Labs Ltd has informed BSE about Outcome of Board Meeting held on November 14, 2016.

14-Nov-2016 12:52 PM

Adinath Bio-Labs Ltd - Standalone Financial Results, Limited Review Report for December 31, 2016

Adinath Bio-Labs Ltd has informed BSE about :

1. Standalone Financial Results for the period ended December 31, 2016

2. Standalone Limited Review for the period ended December 31, 2016

10-Feb-2017 12:47 PM

Adinath Bio-Labs Ltd - Board Meeting Intimation for Results & Closure of Trading Window

Adinath Bio-Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 10, 2017, inter alia, to consider the following business as under:-

- To consider and approve Unaudited financial results for the 3rd quarter ended 31st December, 2016.

Further, the Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 read with Code of Conduct farmed by the Company shall be closed for all designated persons of the Company and their relatives from February 01, 2017 to February 12, 2017 (both days inclusive).

30-Jan-2017 07:03 PM

Adinath Bio-Labs Ltd - Shareholding for the Period Ended December 31, 2016

Adinath Bio-Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016.

18-Jan-2017 06:04 PM

Corporate Details

About Management

2008

- The Company has splits its face value from Rs10/- to Rs1/-.

2009

--Registered Office of the Company has been shifted form "Suite No.18, 2 India Exchange Place, Kolkata - 700001" to "4, N.S.Road, 1st Floor, Kolkata - 700001."

Registered Office

4, N. S. Road, 1st Floor

033-22315718,,,      033-22315718,

investors@adinathbio.com

http://www.adinathbio.com

Registrar Details

Adroit Corporate Service (P) Ltd.